Novakand Pharma AB (publ) (LARK) — Cash Flow Reinvestment Rate
Novakand Pharma AB (publ) (LARK) has a Cash Flow Reinvestment Rate of 0.00x as of June 2026, reinvesting Skr0.00 (capex Skr0.00 ) from operating cash flow of Skr352.00K. See financial flexibility index of Novakand Pharma AB (publ) to measure the company's free cash flow as a share of total liabilities.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Novakand Pharma AB (publ) Cash Flow Reinvestment Rate (2012–2021)
Historical reinvestment intensity for Novakand Pharma AB (publ) across 3 annual periods. Explore LARK debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Novakand Pharma AB (publ) (2012–2021)
Year-by-year capital reinvestment analysis for Novakand Pharma AB (publ). For the full cash flow conversion analysis, see Novakand Pharma AB (publ) cash conversion from operations.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 0.01x | Skr147.73K | Skr22.11 Million | Skr147.73K | ▼ -99.6% |
| 2018 | 1.89x | Skr430.20K | Skr227.60K | Skr430.20K | — |
| 2012 | 0.00x | Skr0.00 | Skr59.21K | Skr0.00 | — |